Safety and Clinical Performance of the Drug Eluting Absorbable Metal Scaffold in the Treatment of Subjects with de Novo Lesions in Native Coronary Arteries at 24-month follow-up - BIOSOLVE-II and BIOSOLVE-III

被引：0

作者：

Haude, Michael ^{[1
]}

Ince, Huseyin ^{[2
,3
]}

Kische, Stephan ^{[4
]}

Abizaid, Alexandre ^{[5
]}

Toelg, Ralph ^{[6
]}

Lemos, Pedro A. ^{[7
]}

Van Mieghem, Nicolas ^{[8
]}

Verheye, Stefan ^{[9
]}

von Birgelen, Clemens ^{[10
]}

Christiansen, Evald ^{[11
]}

Barbato, Emanuele ^{[12
]}

Neumann, Franz-Josef ^{[13
]}

Witzenbichler, Bernhard ^{[14
]}

Kaiser, Christoph ^{[15
]}

Eeckhout, Eric ^{[16
]}

Escaned, Javier ^{[17
]}

Garcia-Garcia, Hector ^{[18
]}

Waksman, Ron ^{[18
]}

机构：

[1] Lukaskrankenhaus Neuss, Neuss, Germany

[2] Univ Rostock, Vivantes Klinikum Friedrichshain & Urban, Berlin, Germany

[3] Univ Rostock, Dept Cardiol, Berlin, Germany

[4] Vivantes, Berlin, Germany

[5] Inst Dante Pazzanese Cardiol, Sao Paulo, SP, Brazil

[6] Segeberger Kliniken, Herzzentrum, Bad Segeberg, Germany

[7] Univ Sao Paulo, Fac Med, InCor, Sao Paulo, SP, Brazil

[8] Erasmus MC, Thoraxctr, Rotterdam, Netherlands

[9] Cardiovasc Ctr ZNA Middelheim, Antwerp, Belgium

[10] Thoraxcentrum Twente, Enschede, Netherlands

[11] Aarhus Univ Hosp, Aarhus, Denmark

[12] Aalst OLV Hosp, Cardiovasc Res Ctr, Aalst, Belgium

[13] Univ Heart Ctr Freiburg Bad Krozingen, Cardiol, Bad Krozingen, Germany

[14] Helios Amper Klinikum, Dachau, Germany

[15] Univ Hosp Basel, Basel, Switzerland

[16] Lausanne Univ Hosp, CH-1011 Lausanne, Switzerland

[17] Hosp Clin San Carlos, IdISSC, Madrid, Spain

[18] MedStar Washington Hosp Ctr, Washington, DC USA

来源：

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2018年 / 72卷 / 13期

关键词：

D O I：

10.1016/j.jacc.2018.08.1152

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

TCT-63

引用

页码：B27 / B28

页数：2

共 40 条

[31] Three-Year Clinical Follow-Up of the FIREHAWK Abluminal Groove-Filled Biodegradable Polymer Sirolimus-Eluting Stent in the Treatment of Single De Novo Native Coronary Lesions: The TARGET I Trial
Xu, Bo
Zhao, Yelin
Yang, Yuejin
Changsheng, Ma
Han, Yaling
Chen, Shao Liang
Li, Hui
Zhang, Ruiyan
Leon, Martin
Gao, Run-Lin
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 64 (11) : B172 - B172
[32] Three-year clinical follow-up of the firehawk abluminal groove-filled biodegradable polymer sirolimus-eluting stent in the treatment of single de novo native coronary lesions: the TARGET 1 trial
Xu, Bo
Zhao, Yelin
Yang, Yuejin
Leon, Martin
Guan, Changdong
CARDIOLOGY, 2014, 129 : 71 - 72
[33] TAXUS II 3-year clinical follow-up: Long-term safety and efficacy post polymer-based paclitaxel-eluting stent implantation for de novo coronary artery lesions
Colombo, A
Banning, A
Silber, S
Hauptmann, KE
Drzewiecki, J
Grube, E
Wijatyk, A
Russell, ME
CIRCULATION, 2005, 112 (17) : U713 - U713
[34] SERIAL ANGIOGRAPHIC FOLLOW-UP AT 6 AND 18 MONTHS AFTER IMPLANTATION OF THE NOVEL NOVOLIMUS-ELUTING BIORESORBABLE VASCULAR SCAFFOLD SYSTEM FOR THE TREATMENT OF SINGLE DE NOVO CORONARY LESIONS: A SUBANALYSIS OF THE DESOLVE NX CLINICAL TRIAL
Costa, Ricardo A.
Abizaid, Alexandre
Costa, Jose de Ribamar
Chamie, Daniel
Abizaid, Andrea
Staico, Rodolfo
Castro, Juliana
Yan, John
Bhat, Vinayak
Morrison, Lynn
Toyloy, Sar
Verheye, Stefan
Sousa, Amanda
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2015, 65 (10) : A1753 - A1753
[35] ABSORB II randomized controlled trial. A clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: Rationale and study design
Diletti, Roberto
Serruys, Patrick W.
Farooq, Vasim
Sudhir, Krishnankutty
Dorange, Cecile
Miquel-Hebert, Karine
Veldhof, Susan
Rapoza, Richard
Onuma, Yoshinobu
Garcia-Garcia, Hector M.
Chevalier, Bernard
AMERICAN HEART JOURNAL, 2012, 164 (05) : 654 - 663
[36] Two-Year Clinical Follow-Up of the FIREHAWK Abluminal Groove-Filled Biodegradable Polymer Sirolimus-Eluting Stent in the Treatment of Patients with De Novo Native Coronary Artery Lesions: The TARGET I Trial
Xu, Bo
Gao, Run-Lin
Lansky, Alexandra
Yang, Yuejin
Ma Changsheng
Han, Yaling
Chen, Shao Liang
Li, Hui
Zhang, Ruiyan
Fu, Guosheng
Yuan, Zuyi
Huo, Yong
Li, Wei
Zhao, Yelin
Leon, Martin
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2013, 62 (18) : B7 - B8
[37] Late Safety Efficacy, and Cost-Effectiveness of a Zotarolimus-Eluting Stent Compared With a Paclitaxel-Eluting Stent in Patients With De Novo Coronary Lesions 2-Year Follow-Up From the ENDEAVOR IV Trial (Randomized, Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary, Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions)
Leon, Martin B.
Kandzari, David E.
Eisenstein, Eric L.
Anstrom, Kevin J.
Mauri, Laura
Cutlip, Donald E.
Nikolsky, Eugenia
O'Shaughnessy, Charles
Overlie, Paul A.
Kirtane, Ajay J.
McLaurin, Brent T.
Solomon, Stuart L.
Douglas, John S., Jr.
Popma, Jeffrey J.
JACC-CARDIOVASCULAR INTERVENTIONS, 2009, 2 (12) : 1208 - 1218
[38] Late-Term Clinical Outcomes With Zotarolimus- and Sirolimus-Eluting Stents 5-Year Follow-Up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions)
Kandzari, David E.
Mauri, Laura
Popma, Jeffrey J.
Turco, Mark A.
Gurbel, Paul A.
Fitzgerald, Peter J.
Leon, Martin B.
JACC-CARDIOVASCULAR INTERVENTIONS, 2011, 4 (05) : 543 - 550
[39] The impact of mandatory angiographic follow-up on the one-year clinical and angiographic results from endeavor IV: A randomized comparison of the endeavor drug (ABT-578) eluting stent system vs. Taxus in de novo native coronary lesions
Leon, Martin B.
Popma, Jeffrey
O'Shaunessy, Charlie
Overlie, Paul
McLaurin, Brent
Solomon, Stuart
Kinane, Ajay
Mauri, Laura
Fitzgerald, Peter
Thompson, Kweli
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 51 (10) : B46 - B46
[40] Long-Term Clinical and Economic Analysis of the Endeavor Drug-Eluting Stent Versus the Driver Bare-Metal Stent 4-Year Results From the ENDEAVOR II Trial (Randomized Controlled Trial to Evaluate the Safety and Efficacy of the Medtronic AVE ABT-578 Eluting Driver Coronary Stent in De Novo Native Coronary Artery Lesions)
Eisenstein, Eric L.
Wijns, William
Fajadet, Jean
Mauri, Laura
Edwards, Rex
Cowper, Patricia A.
Kong, David F.
Anstrom, Kevin J.
JACC-CARDIOVASCULAR INTERVENTIONS, 2009, 2 (12) : 1178 - 1187

← 1 2 3 4 →